LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis

PURPOSE: Gefitinib resistance limits the therapeutic efficacy of gefitinib to lung adenocarcinoma (LUAD). The goal of this research is to learn more about the lncRNA AFAP1-AS1 and how it functions in gefitinib-resistant LUAD cells. METHODS: RT-qPCR was performed to test the expression of AFAP1-AS1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Tao, Jiang, Ping, Fu, Jun, Zhang, Yongjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829986/
https://www.ncbi.nlm.nih.gov/pubmed/36636455
http://dx.doi.org/10.2147/TCRM.S374162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829986/
https://www.ncbi.nlm.nih.gov/pubmed/36636455
http://dx.doi.org/10.2147/TCRM.S374162

Ejemplares similares